Enabled by the recent U.S. Food and Drug Administration (FDA) 510(k) clearance of ELISIO-HX, NIPRO CORPORATION, through its U.S.-based subsidiary Nipro Medical Corporation, has announced the U.S. commercial launch of the medium-cutoff dialyzer featuring super high-flux membrane technology.

For years, dialysis providers have sought ways to expand the removal of larger middle molecules, substances associated with inflammation, and other complications that are not effectively cleared by conventional high-flux dialysis. Until now, broader adoption of therapies designed to address this challenge has been limited due to supply constraints, high costs, operational complexity, and infrastructure requirements.

With the introduction of ELISIO-HX, U.S. providers now have greater access to an expanded hemodialysis therapy with a strong global track record and robust supply capabilities that enhances middle molecule removal. The membrane incorporates a highly controlled and precisely engineered pore structure that is designed to extend the removal profile of larger middle molecules while maintaining albumin retention, an important consideration in preserving patients’ nutritional status.

Since the ELISIO-HX is compatible with existing hemodialysis infrastructure, physicians and providers can incorporate expanded hemodialysis into routine clinical practice without purchasing new machines, fundamentally changing treatment workflows or retraining staff.

Expanded hemodialysis with ELISIO-HX may be suitable for a broader range of patients, including those with vascular access limitations or other considerations that can make high-volume therapies more challenging to deliver.

Visit NIPRO for more information